Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
129.5 USD | -1.22% | -1.15% | +18.78% |
01:48pm | Merck Says Phase 3 Trial of Keytruda in Triple Negative Breast Cancer Met Overall Survival Endpoint | MT |
05-27 | ANALYST RECOMMENDATIONS : Boeing, Dell, Merck, RyanAir... |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+18.78% | 328B | |
+38.51% | 727B | |
+31.99% | 594B | |
-6.23% | 354B | |
+1.35% | 277B | |
+14.72% | 243B | |
+7.62% | 205B | |
-5.97% | 203B | |
+6.19% | 164B | |
+0.31% | 164B |
- Stock Market
- Equities
- MRK Stock
- News Merck & Co., Inc.
- Merck & Co. Said to Seek Japanese Regulatory Nod for COVID-19 Pill